Category: CDE

Categories
CDE Diabetes

Flashcards: Hypoglycemia in Adults (Chapter 14 Update)

Sharpen your ability to prevent and manage the most common complication of insulin therapy.

The 2023 Guidelines mark a paradigm shift in hypoglycemia management—moving beyond simple treatment protocols to a proactive focus on prevention, risk stratification, and the use of advanced technology. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the critical updates regarding prevention strategies, glucagon administration, and the management of impaired awareness.

Key Topics Covered:

  • Prevention vs. Treatment: Understanding why prevention is the primary goal and the requirement to reassess insulin/secretagogue doses at every visit.

  • Impaired Awareness (IAH): Memorizing the recommendation to screen all individuals with Type 1 diabetes (and relevant Type 2 patients) for Impaired Awareness of Hypoglycemia.

  • Acute Management: Reviewing the specific “15 g” protocol for fast-acting carbohydrates (e.g., glucose tablets) to ensure the fastest rise in blood glucose.

  • Severe Hypoglycemia: Identifying the indications for glucagon prescription and the mandatory counseling of support persons on its administration.

  • Technology & Education: Recognizing the evidence-based role of Continuous Glucose Monitoring (CGM) and structured education programs for high-risk individuals.

Categories
CDE Diabetes

Practice Exam: Hypoglycemia in Adults (Chapter 14 Update)

Hypoglycemia remains the most frequent and potentially dangerous complication for many individuals treated with insulin or insulin secretagogues. The 2023 Guidelines emphasize a shift from simply treating low blood glucose to actively preventing it through risk stratification, education, and the use of technology.

This practice exam tests your ability to apply the latest recommendations regarding the prevention, recognition, and management of hypoglycemia, including protocols for severe events and impaired awareness.

Key Concepts Covered in This Exam:

  • Prevention First: Understanding that preventing hypoglycemia is safer and more effective than treating it, and knowing how to reassess medication doses at every visit.

  • Impaired Awareness of Hypoglycemia (IAH): Screening all individuals with Type 1 diabetes (and those with Type 2 on insulin/secretagogues) for IAH and implementing structured education or technology solutions.

  • Treatment Protocols: Applying the correct treatment steps—administering fast-acting carbohydrates (e.g., glucose tablets) to achieve the fastest rise in blood glucose, followed by a snack or meal to prevent recurrence.

  • Severe Hypoglycemia: Mastering the management of severe events, including the prescription of glucagon and the critical role of counseling support persons on its administration.

  • Role of Technology: Identifying when Continuous Glucose Monitoring (CGM) should be used to detect and prevent hypoglycemia in high-risk individuals.

1. Case: A patient with type 2 diabetes has advanced hepatic disease. When using glucagon for hypoglycemia treatment, what should be considered?

2. Case: A diabetes educator is developing a comprehensive hypoglycemia prevention program. According to the guidelines, which combination of strategies has the strongest evidence for reducing hypoglycemia in patients with type 1 diabetes?

3. According to Diabetes Canada, what blood glucose level is used as an alert value to classify hypoglycemia in individuals treated with insulin or insulin secretagogues?

4. Case: A patient with type 1 diabetes who consumes more than 2 alcoholic drinks experiences severe hypoglycemia. After glucagon administration, recovery is slower than expected. What explains this?

5. Case: A diabetes educator is counselling the spouse of a patient with type 1 diabetes about nocturnal hypoglycemia. What should the educator explain about the sympathoadrenal response during sleep?

6. A patient treated with a sulfonylurea experiences a hypoglycemic episode. Which statement about glucagon use in this patient is correct?

7. Case: A 62-year-old patient with type 2 diabetes and chronic kidney disease (CKD stage 3) is on insulin therapy. According to the guidelines, which insulin formulation may be beneficial?

8. Which antihyperglycemic agents are associated with the lowest risk of hypoglycemia according to the guidelines?

9. Which symptoms are classified as adrenergic (autonomic) symptoms of hypoglycemia?

10. According to the guidelines, how much can 15 g of oral glucose be expected to raise blood glucose within 20 minutes?

11. Case: A 58-year-old patient with type 2 diabetes on insulin glargine-U-100 experiences frequent nocturnal hypoglycemia. According to the guidelines, which insulin should be considered to reduce this risk?

12. Case: A 70-year-old patient with type 2 diabetes has an A1C of 6.5% and experiences recurrent hypoglycemia. Which management strategy is most appropriate?

13. Case: A patient with type 1 diabetes is planning to engage in 45 minutes of cardio exercise. According to the guidelines, what pre-exercise strategy should be considered?

14. Case: A 55-year-old patient with type 2 diabetes has a history of cardiovascular disease and experiences symptomatic hypoglycemia. Based on the evidence regarding hypoglycemia and cardiovascular outcomes, what is the most appropriate clinical consideration?

15. What is the recommended approach for individuals at high risk of severe hypoglycemia regarding glucagon?

16. Which validated questionnaire is MOST commonly used to measure fear of hypoglycemia (FoH)?

17. What percentage of individuals with type 1 or type 2 diabetes (treated with insulin or insulin secretagogues) self-report at least one episode of hypoglycemia in a given year?

18. What is the recommended initial treatment for Level 1 or 2 hypoglycemia according to Diabetes Canada guidelines?

19. Case: A patient with type 1 diabetes is found unconscious by a family member at home. The family member has been trained to use glucagon. What is the recommended dose of subcutaneous or intramuscular glucagon?

20. Which psychoeducational program has been shown to reduce the prevalence of IAH and frequency of hypoglycemia?

21. Case: A 45-year-old woman with type 1 diabetes reports no longer experiencing warning symptoms before hypoglycemic episodes. She has had 3 episodes of severe hypoglycemia in the past year. What intervention is most appropriate according to the guidelines?

22. Case: An 80-year-old patient with type 2 diabetes, cognitive impairment, and recurrent hypoglycemia is being reviewed. According to the guidelines, what should be the priority in this patient’s management?

23. When comparing intranasal glucagon to injectable glucagon for treating severe hypoglycemia, what advantage does intranasal administration provide according to the evidence?

24. How long should hypoglycemia be avoided to potentially reverse impaired awareness of hypoglycemia (IAH)?

25. Case: A diabetes educator is developing materials for patients about hypoglycemia treatment. Which of the following is NOT considered an appropriate treatment option for Level 1-2 hypoglycemia?

26. What glucose level defines Level 2 hypoglycemia according to the International Hypoglycemia Study Group classification?

27. Case: A 35-year-old patient with type 1 diabetes asks about continuous glucose monitoring (CGM). According to the guidelines, what is a key benefit of CGM for hypoglycemia prevention?

28. Case: A patient on a low-carbohydrate diet experiences Level 3 hypoglycemia and receives glucagon. What should be considered about the treatment effect?

29. Case: A patient is found to have Level 3 hypoglycemia and is conscious but unable to swallow. What is the appropriate treatment?

30. Which classification of hypoglycemia is defined by the presence of neuroglycopenic symptoms requiring external assistance to treat?

31. A diabetes educator is counselling a patient who has experienced impaired awareness of hypoglycemia (IAH). Which validated tool can be used to screen for IAH?

32. After treating a hypoglycemic episode, when should a patient consume a snack containing 15 g carbohydrate and a protein source?

33. Case: A patient with type 1 diabetes and recurrent severe hypoglycemia is being considered for advanced interventions. According to the guidelines, which surgical option may be considered?

34. What is the time interval recommended for retesting blood glucose after initial hypoglycemia treatment?

35. What is the prevalence of fear of hypoglycemia (FoH) among individuals with type 1 and type 2 diabetes treated with insulin and/or insulin secretagogues?

36. A patient asks about the relationship between recurrent hypoglycemia and cognitive function. Based on the evidence presented in the guidelines, what is the most accurate response?

37. Which of the following is a risk factor for severe hypoglycemia?

38. A diabetes healthcare team is debating the use of rtCGM versus isCGM for a patient with type 1 diabetes and frequent exercise-related hypoglycemia. Based on the guidelines, which statement is most accurate?

39. What dose of intranasal glucagon is recommended for treating severe hypoglycemia?


 

Categories
CDE Diabetes

Study Guide: Hypoglycemia in Adults (Chapter 14)

1. Chapter Overview

Hypoglycemia is the major barrier to achieving glycemic targets. For the CDE exam, you must distinguish between the “levels” of hypoglycemia (a change in terminology from mild/moderate/severe) and know the specific treatment protocols for conscious versus unconscious individuals. The 2023 update places a heavy emphasis on prevention using technology (CGM) and the use of nasal glucagon.

2. Definition and Classification

Hypoglycemia is defined not strictly by glucose levels alone but by the severity of symptoms and the risk of adverse outcomes.

  • Alert Value: A glucose level of should alert the individual and clinician to potential hypoglycemia in those treated with insulin or insulin secretagogues.
Level 1 ( but
  • Autonomic symptoms present.
  • No neuroglycopenic symptoms.
  • Self-treatable
Level 2 (
  • Neuroglycopenic symptoms appear.
  • Usually self-treatable (does not require assistance).

Level 3 (Severe) (No specific glucose threshold)

  • Characterized by altered mental/physical status.
  • Requires external assistance for recovery (cannot self-treat).

3. Clinical Presentation

Symptoms typically progress from adrenergic (autonomic) to neuroglycopenic.

  • Adrenergic (Early/Warning): Trembling, palpitations, sweating, anxiety, hunger, nausea, tingling.
  • Neuroglycopenic (Brain Glucose Deprivation): Difficulty concentrating, confusion, weakness, vision changes, slurred speech, dizziness, headache.
    • Note: Individuals with Impaired Awareness of Hypoglycemia (IAH) may experience neuroglycopenic symptoms without prior adrenergic warning signs

4. Risk Factors

Identifying “high-risk” patients is a core competency for the CDE exam.

Key Risk Factors for Severe Hypoglycemia:

  • History: Prior episode of severe hypoglycemia.

  • Demographics: Advancing age, long duration of diabetes, low health literacy, food insecurity.
     
  • Physiological: Impaired Awareness of Hypoglycemia (IAH), autonomic neuropathy, chronic kidney disease (CKD), cognitive impairment.
  • Treatment: Use of insulin or insulin secretagogues (sulfonylureas/meglitinides), strict glycemic targets (low A1C).

Impaired Awareness of Hypoglycemia (IAH):

  • Occurs when the threshold for autonomic warning symptoms drops lower than the threshold for neuroglycopenia.
  • Screening: All individuals with type 1 diabetes and those with type 2 diabetes on insulin/secretagogues should be screened for IAH.
  • Reversibility: Strict avoidance of hypoglycemia for 2 days to 3 months can restore awareness.

5. Prevention Strategies

Prevention is preferred over treatment

Pharmacotherapy Adjustments:

  • Insulin: Switch from NPH to long-acting basal analogues (glargine U-300, degludec) to reduce nocturnal hypoglycemia.

    • CDE Gem: Degludec and glargine U-300 are “second-generation” analogues with lower hypoglycemia risk than glargine U-100 or detemir.
  • Type 2 Agents: Prioritize agents with low hypoglycemia risk (GLP-1 RA, DPP-4 inhibitors, SGLT2 inhibitors) over sulfonylureas where possible.

Technology:

  • CGM: Continuous Glucose Monitoring (rtCGM or isCGM) is recommended for those with T1D or T2D on insulin/secretagogues to reduce time in hypoglycemia.

Technology:

  • CGM: Continuous Glucose Monitoring (rtCGM or isCGM) is recommended for those with T1D or T2D on insulin/secretagogues to reduce time in hypoglycemia.

Education:

  • Counsel support persons on glucagon administration.

  • Screen for Fear of Hypoglycemia (FoH), which can lead to “defensive snacking” and maintaining high BG.

6. Treatment Protocol

A. Level 1 & 2 (Conscious & Able to Swallow):

Treat: Ingest 15 g of fast-acting carbohydrate (glucose tablets, sucrose solution).

  • Examples: 4x 4 gm glucose tablets, 150 mL (2/3 cup) juice or regular soft drink, 1 tablespoon honey

Wait: Wait 15 minutes.

Retest: Check BG. If still , treat again with another 15 g.

Maintain: Once BG is safe ():
  • Eat usual meal if due within 1 hour.
  • If meal is hour away, eat a snack (15 g carb + protein source).

B. Level 3 (Conscious but requires help):

  • Oral: 20 g carbohydrate if able to swallow.
  • Glucagon: If unable to swallow, administer Glucagon (3 mg Intranasal OR 1 mg SC/IM).

C. Level 3 (Unconscious):

  • No IV Access: Glucagon 1 mg SC/IM or 3 mg Intranasal. Call emergency services.
    IV Access (Hospital): 10–25 g glucose IV (D50W) over 1–3 minutes.

Important Notes on Glucagon:

  • Intranasal (IN) Glucagon: Effective for both T1D and T2D; easier and faster to administer than injectable.

  • Alcohol: Glucagon effectiveness is reduced if the patient has consumed standard drinks recently.
  • Sulfonylureas: Glucagon is less useful for hypoglycemia caused by secretagogues as it may stimulate further insulin release.

7. Special Considerations

  • Driving: Review safe driving guidelines at every visit.
  • Exercise: To prevent exercise-induced lows, reduce insulin or increase carbs 60-90 minutes pre-exercise.

7. Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section of the Guidelines (Pages 552-554).

Counseling & Screening

  • Universal Counselling: All individuals on insulin or insulin secretagogues (and their support persons) must be counselled on risk, prevention, recognition, and treatment of hypoglycemia.

  • Every Visit Review: At every clinical encounter, review the recent history of hypoglycemia, including frequency, causes, and driving safety.
  • Screen for IAH: Screen for Impaired Awareness of Hypoglycemia (IAH) using a careful history or validated questionnaires.
  • Screen for Fear: Screen for Fear of Hypoglycemia (FoH) and refer to mental health professionals if persistent.

Prevention Strategies (High-Risk Individuals)

  • Technology: Use Continuous Glucose Monitoring (CGM) or increased capillary monitoring to identify unrecognized hypoglycemia.
    • Note: Real-time CGM (rtCGM) is Grade A evidence for Type 1 Diabetes.
  • Insulin Choice:
    • Basal vs. NPH: Long-acting analogues (glargine, detemir, degludec) are preferred over NPH insulin to reduce risk.
    • 2nd Gen vs. 1st Gen: Second-generation basal analogues (glargine U-300, degludec) are preferred over first-generation (glargine U-100, detemir) to reduce nocturnal hypoglycemia.
  • Education: Structured diabetes education and psychobehavioural interventions (e.g., Blood Glucose Awareness Training) should be utilized.

Management of Recurrent/Severe Hypoglycemia

  • Strict Avoidance: For those with IAH or recurrent severe episodes, aim for strict avoidance of hypoglycemia and potentially relax glycemic targets for up to 3 months to restore awareness.
  • Pumps & Sensors: Consider CSII (pumps), CGM, or sensor-augmented pumps for Type 1 Diabetes.
  • Transplantation: Islet cell or pancreas transplantation may be considered for T1D with recurrent severe hypoglycemia.

Treatment Recommendations (The Protocols)

  • Level 1 & 2: Ingest 15 g carbohydrate (glucose/sucrose preferred). Retest in 15 mins. Retreat if BG .
  • Level 3 (Conscious):
    • If able to swallow: 20 g carbohydrate.
    • Or: Glucagon 3 mg Intranasal or 1 mg SC/IM.
  • Level 3 (Unconscious):
    • No IV: Glucagon (3 mg IN or 1 mg SC/IM). Call emergency services.
    • With IV: 10–25 g glucose (20–50 mL of D50W) intravenously over 1–3 minutes.
  • Support Persons: Must be taught how to administer glucagon (SC, IM, or IN).
  • Post-Treatment: Eat usual meal or snack (15 g carb + protein) if meal is hour away.

Reference:  

Lega IC, Yale JF, Chadha A, et al. Hypoglycemia in Adults. Canadian Journal of Diabetes. 2023;47(7):548-559. doi:10.1016/j.jcjd.2023.08.003
Categories
CDE Diabetes

Flashcards: Pharmacologic Glycemic Management of Type 2 Diabetes (Chapter 13 Update)

Master the 2024 updates to pharmacotherapy for Type 2 diabetes.

The 2024 Update to the Clinical Practice Guidelines introduces critical shifts in the management of Type 2 diabetes, prioritizing cardiorenal protection alongside glycemic control. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the latest evidence-based recommendations for selecting antihyperglycemic agents based on comorbidities like heart failure, chronic kidney disease (CKD), and cardiovascular risk.

Key Topics Covered:

  • Initial Therapy: Confirming metformin as the first-line agent for most patients and knowing when to initiate insulin immediately.

  • Cardiorenal Protection: Identifying the specific indications for GLP-1 Receptor Agonists (GLP1-RA) and SGLT2 Inhibitors in patients with atherosclerotic cardiovascular disease (ASCVD), heart failure, or CKD.

  • Glycemic Targets: Recalling when to add second-line agents (e.g., when A1C is >1.5% above target) and the benefits of combination therapy.

  • Safety & Side Effects: Reviewing the risk of euglycemic DKA with SGLT2 inhibitors and contraindications for GLP1-RAs.

  • Weight Management: Understanding the role of specific agents (e.g., Semaglutide, Tirzepatide) in weight loss and metabolic health.

Categories
CDE Diabetes Uncategorized

Practice Exam: Pharmacologic Glycemic Management (2024 Update)

You have reviewed the study guide for the Diabetes Canada 2024 Pharmacologic Update, and now it is time to test your knowledge.

This is arguably the most critical section of the CDE exam. The 2024 Guidelines have cemented a paradigm shift in diabetes care: we are no longer treating “sugar” in isolation; we are treating risk. The exam will require you to look beyond the A1C number and identify patients who need Cardiorenal Protection regardless of their glycemic control.

What to expect in this quiz: This practice exam focuses on the complex decision trees introduced in the latest update. You will be tested on:

  • The “Cardiorenal Path”: Identifying patients with ASCVD, Heart Failure, or CKD who require an SGLT2 inhibitor or GLP-1 RA, even if their A1C is already at target.

  • The “1.5% Rule”: Knowing when to bypass monotherapy and initiate Metformin + a second agent immediately at diagnosis.

  • Symptomatic Decompensation: Recognizing the clinical signs (weight loss, severe hyperglycemia) that mandate the immediate start of Insulin.

  • Heart Failure Nuances: Specifically recalling that SGLT2 inhibitors are the only class proven to reduce hospitalizations for heart failure.

Please go to Practice Exam: Pharmacologic Glycemic Management (2024 Update) to view this quiz

Categories
CDE Diabetes

Study Guide: Pharmacologic Glycemic Management (2024 Update)

1. Chapter Overview: The "Organ Protection" Shift

The 2024 update reinforces a major paradigm shift: we are no longer just treating “sugar”; we are treating risk. The guidelines prioritize agents with proven cardiovascular and renal benefits (Cardiorenal Protection) for high-risk patients, often independent of their A1C levels.

For the CDE exam, you must distinguish between the “Glycemic Path” (lowering A1C) and the “Cardiorenal Path” (reducing heart failure, kidney disease progression, and stroke).

2. Key Messages (The "Gold Nuggets")

  • Metformin is (Usually) First: Metformin remains the initial agent of choice for most people due to safety, low cost, and efficacy.

  • The “Symptomatic” Exception: If a patient presents with metabolic decompensation (e.g., significant weight loss, severe hyperglycemia, ketosis), Insulin should be initiated immediately.

  • Cardiorenal Trumps A1C: In patients with Atherosclerotic CVD (ASCVD), Heart Failure (HF), or Chronic Kidney Disease (CKD), use an agent with proven benefit (SGLT2i or GLP-1 RA) even if their A1C is already at target.

  • Early Combination: If the A1C is >1.5% above target at diagnosis, start with Metformin + a second agent immediately (don’t wait 3 months).

3. Cardiorenal Protection (The "Big Three")

A. Atherosclerotic CVD (ASCVD)

  • Definition: History of MI, stroke, or revascularization.

  • Recommended Agents:

    • GLP-1 RA (with proven CVD benefit).

    • SGLT2i (with proven CVD benefit).

  • Goal: Reduce Major Adverse Cardiovascular Events (MACE).

B. Heart Failure (HF)

  • Definition: Reduced Ejection Fraction (HFrEF) or Preserved Ejection Fraction (HFpEF).

  • Recommended Agent: SGLT2 Inhibitor

C. Chronic Kidney Disease (CKD)

  • Definition: eGFR <60 mL/min or Albuminuria (ACR >2 mg/mmol).

  • Recommended Agents:

    • SGLT2 Inhibitor: Primary choice to slow progression.

    • GLP-1 RA: Alternative if SGLT2i is contraindicated or additional lowering is needed.

4. Drug Classes & Characteristics

ClassKey
Examples		BenefitsConsiderations
SGLT2 InhibitorsEmpagliflozin, Dapagliflozin, CanagliflozinHF & CKD protection, Weight loss, BP reduction.Risk of Genital Infections, DKA (rare), Amputation (Canagliflozin).
GLP-1 RASemaglutide, Liraglutide, DulaglutideASCVD protection, Significant Weight loss, No Hypo.GI side effects (nausea/vomiting), Cost, Injection (mostly).
GIP/GLP-1 RATirzepatideHighest efficacy for A1C and Weight loss.GI side effects.
DPP-4 InhibitorsSitagliptin, LinagliptinWeight neutral, Well tolerated.No CV/Renal benefit (neutral). Do not combine with GLP-1.
SulfonylureasGliclazide, GlimepirideLow cost, High efficacy.Weight Gain, Hypoglycemia risk.

5. Clinical Decision Algorithm (Summary)

Step 1: Assessment

  • Is the patient symptomatic/decompensated? -> Insulin +/- Metformin.

  • No? -> Proceed to Step 2.

Step 2: Baseline Therapy

  • Lifestyle Modifications + Metformin.

  • Exam Tip: If A1C is >1.5% above target, start Metformin + Second Agent.

Step 3: Cardiorenal Assessment (The Critical Junction)

  • Does the patient have ASCVD, HF, or CKD?

    • YES: Add SGLT2i or GLP-1 RA with proven benefit. (Do this regardless of A1C).

    • NO: Choose second agent based on goals:

      • Need Weight Loss? -> Tirzepatide, Semaglutide (GLP-1).

      • Avoid Hypo? -> DPP-4, SGLT2i, GLP-1.

      • Cost/Access Issues? -> Sulfonylurea, Insulin (NPH/Regular), TZDs.

Step 4: Monitoring

  • If not at target in 3–6 months, add another agent from a different class.

6. 2024 Diabetes Canada Clinical Practice Guidelines Recommendations

These are the “Must Memorize” graded recommendations.

  1. First Line: Metformin should be the initial agent of choice in most people with type 2 diabetes.

  2. Cardiorenal Risk: In adults with T2D and ASCVD, CKD, or HF, an agent with proven benefit (SGLT2i or GLP-1 RA) should be added to metformin.

    • Note: This decision is independent of A1C.

  3. Heart Failure: SGLT2 inhibitors are specifically recommended for patients with a history of Heart Failure to reduce hospitalization.

  4. Combination: In patients with A1C >1.5% above target, antihyperglycemic agents should be initiated concurrently (Metformin + Second Agent).

Reference:

Shah B, Bajaj HS, Butalia S, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2024 Update. Canadian Journal of Diabetes. 2024;48:415-424. doi:10.1016/j.jcjd.2020.08.001
Categories
CDE Diabetes

Flashcards: Glycemic Management in Adults with Type 1 Diabetes (Chapter 12)

Achieving optimal glycemic control in Type 1 diabetes requires a sophisticated balance of insulin regimens, monitoring technologies, and lifestyle management. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the Diabetes Canada Clinical Practice Guidelines recommendations for basal-bolus therapy, pump usage, and the integration of new technologies like continuous glucose monitoring.

Key Topics Covered:

  • Insulin Regimens: Differentiating between Multiple Daily Injections (MDI) and Continuous Subcutaneous Insulin Infusion (CSII) as standards of care.

  • Pharmacotherapy: Understanding the advantages of rapid-acting and long-acting insulin analogues over older formulations for reducing hypoglycemia and improving A1C.

  • Technology & Monitoring: Identifying the specific benefits of Real-Time Continuous Glucose Monitoring (rtCGM) and Sensor-Augmented Pumps (SAP) for high-risk individuals.

  • Hypoglycemia Prevention: Reviewing strategies for patients with hypoglycemia unawareness, including standardized education and technology.

  • Adjunctive Therapies: Recalling the current evidence and limitations regarding non-insulin agents like metformin, GLP-1 receptor agonists, and SGLT2 inhibitors.

Categories
CDE Diabetes

Practice Exam: Glycemic Management in Adults with Type 1 Diabetes (Chapter 12)

Effective management of Type 1 diabetes requires a complex balance of insulin replacement, monitoring, and lifestyle adaptation. This exam tests your understanding of the Diabetes Canada Clinical Practice Guidelines regarding insulin pharmacotherapy, delivery systems, and the prevention of hypoglycemia.

Key Concepts Covered in This Exam:

  • Insulin Regimens: Differentiating between basal-bolus injection therapy and continuous subcutaneous insulin infusion (CSII), and understanding why these are the preferred standards of care.
  • Pharmacotherapy: Identifying the advantages of long-acting analogues (glargine, detemir, degludec) over NPH for reducing nocturnal hypoglycemia , and the role of rapid-acting analogues.
  • Hypoglycemia Prevention: Recognizing strategies for patients with hypoglycemia unawareness, including the use of sensor-augmented pumps (SAP) and standardized education programs.
  • Technology Integration: Understanding the indications for Real-Time Continuous Glucose Monitoring (rtCGM) to improve A1C and reduce severe hypoglycemia.
  • Adjunctive Therapies: Knowing the current limitations and risks (e.g., DKA) associated with non-insulin agents like SGLT2 inhibitors and GLP-1 receptor agonists in Type 1 diabetes.

Please go to Practice Exam: Glycemic Management in Adults with Type 1 Diabetes (Chapter 12) to view this quiz

Categories
CDE Diabetes

Study Guide: Glycemic Management in Adults with Type 1 Diabetes (Chapter 12)

1. Chapter Overview

This chapter establishes the standard of care for Type 1 Diabetes (T1D): Basal-Bolus injection therapy (MDI) or Continuous Subcutaneous Insulin Infusion (CSII/Pump).

For the CDE exam, the focus is rarely on “how to inject,” but rather on insulin pharmacokinetics (why we choose analogues over human insulin) and the indications for advanced therapies (when to switch from MDI to Pump or Sensor-Augmented Pump). You must also understand the emerging, though cautious, data on non-insulin adjunctive therapies.

2. Key Messages (The "Gold Nuggets")

  • The Standard: Basal-bolus (MDI) or CSII are the only preferred regimens. Premixed insulins are generally not suitable for adults with T1D.

  • Safety First: The primary driver for choosing long-acting basal analogues (e.g., glargine, detemir, degludec) over NPH is the reduction of hypoglycemia, specifically nocturnal hypoglycemia.

  • Rapid is Better: Rapid-acting insulin analogues (RAIA) are preferred over short-acting (regular) insulin because they improve postprandial glucose and lower A1C without increasing hypoglycemia.

  • The Pump Candidate: CSII is not just for people with high A1C. It is specifically indicated for those with severe hypoglycemia, hypoglycemia unawareness, or a significant “Dawn Phenomenon.”

3. Insulin Pharmacotherapy

A. Basal Insulins

  • Goal: Control glucose in the fasting state and between meals.

  • Long-Acting Analogues (Detemir, Glargine U-100): Lower fasting glucose and less nocturnal hypoglycemia compared to NPH.

  • Ultra-Long Acting (Glargine U-300, Degludec):

    • Glargine U-300 (Toujeo): Longer duration (>30 hours) and flatter profile than U-100.

    • Degludec (Tresiba): Duration of ~42 hours. Associated with less nocturnal hypoglycemia and lower total insulin dose compared to glargine or detemir. Allows for flexible dosing timing.

B. Bolus Insulins

  • Goal: Control glycemic rise at meals.

  • Rapid-Acting Analogues (Aspart, Lispro, Glulisine): Administer 0–15 minutes before meals.

  • Faster-Acting Aspart (Fiasp): Can be administered at the start of the meal or up to 20 minutes after starting. Demonstrated superior postprandial control vs. insulin aspart.

4. Advanced Technologies: CSII and SAP

A. Continuous Subcutaneous Insulin Infusion (CSII / Pump)

  • Indications: Consider CSII if MDI is optimized but targets are not met, OR if the patient has:

    • Significant glucose variability.

    • Frequent severe hypoglycemia or hypoglycemia unawareness.

    • Significant “Dawn Phenomenon” (rise in BG early morning).

    • Very low insulin requirements (requiring micro-dosing).

    • Women contemplating pregnancy.

  • Outcomes: Lowers A1C by ~0.3% compared to MDI; improves Quality of Life (QOL) and Treatment Satisfaction.

B. Sensor-Augmented Pump (SAP)

  • Definition: Insulin pump combined with Continuous Glucose Monitoring (CGM).

  • Benefit: A1C reduction is superior to MDI or Pump alone.

  • Low Glucose Suspend: Pumps equipped with this feature (stopping insulin when low) significantly reduce nocturnal hypoglycemia without raising A1C or causing ketoacidosis.

5. Adjunctive Therapies (Non-Insulin)

The guidelines reviewed using Type 2 medications in Type 1 diabetes. Note: These are generally off-label uses.

  • Metformin: May reduce insulin requirements and lead to modest weight loss, but does NOT result in sustainable A1C improvement.

  • GLP-1 Receptor Agonists (e.g., Liraglutide): Associated with weight loss and insulin dose reduction, but inconsistent A1C results.

  • SGLT2 Inhibitors:

    • Showed reduction in A1C and weight.

    • Major Warning: Significant risk of Diabetic Ketoacidosis (DKA), including “euglycemic DKA” (DKA with normal blood sugars). Currently, they do not have an indication for T1D in Canada.

6. Diabetes Canada Clinical Practice Guidelines Recommendations

Key Recommendations to Memorize:

  1. Regimen: Basal-bolus injection or CSII should be used to achieve glycemic targets. (Grade A, Level 1A).

  2. Basal Choice: A long-acting insulin analogue (Detemir, Glargine, Degludec) may be used in place of NPH to reduce the risk of nocturnal hypoglycemia. (Grade B, Level 2).

  3. Degludec Specifics: Degludec may be used instead of detemir or glargine U-100 to reduce nocturnal hypoglycemia. (Grade B/C).

  4. Bolus Choice: Rapid-acting analogues should be used over regular insulin to improve A1C and minimize hypoglycemia. (Grade B, Level 2).

  5. Hypoglycemia Unawareness: Strategies to restore awareness include:

    • Standardized education (Grade A, Level 1A).

    • Relaxed glycemic targets for up to 3 months (Grade C, Level 3).

    • Sensor-Augmented Pump with Low Glucose Suspend (Grade B, Level 2).

  6. Technology: In adults not achieving targets (on MDI or CSII), CGM should be considered to improve A1C. (Grade B, Level 2).

Reference: 

McGibbon A, Adams L, Ingersoll K, Kader T, Tugwell B. Glycemic Management in Adults With Type 1 Diabetes. Canadian Journal of Diabetes. 2018;42:S80-S87. doi:10.1016/j.jcjd.2017.10.012
Categories
CDE Diabetes Uncategorized

Flashcards: Nutrition Therapy (Chapter 11)

Test your recall on the dietary strategies that drive diabetes management.

Nutrition therapy is a fundamental pillar of diabetes care, capable of lowering A1C by up to 2.0%. These flashcards are designed to help pharmacists and healthcare professionals quickly review the evidence-based recommendations for macronutrient distribution, dietary patterns, and specific food choices that improve metabolic outcomes.

Key Topics Covered:

  • Macronutrient Ranges: Memorizing the flexible distribution ranges for carbohydrates (45–60%), protein (15–20%), and fat (20–35%).

  • Dietary Patterns: Identifying specific benefits of Mediterranean, DASH, Vegetarian, and Portfolio diets for glycemic control and cardiovascular health.

  • Carbohydrate Quality: Understanding the role of Glycemic Index (GI) and the recommended daily target for dietary fibre (30–50 g).

  • Fat & Sugar Limits: Recalling the specific thresholds for saturated fat intake (<9% of total energy) and added sugars (<10% of total energy).

  • Clinical Considerations: Reviewing guidelines for alcohol consumption, non-nutritive sweeteners, and vitamin supplementation.